Genetic Variations May Identify Best Candidates for Preventive Breast Cancer Drugs

Genetic Variations May Identify Best Candidates for Preventive Breast Cancer Drugs

By
Dana Sparks

June 10, 2013

Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. Mayo Clinic oncologist, James Ingle, M.D., says, “Our findings are important, because we identified genetic factors that could eventually be used to select women who should be offered the drugs for prevention.”

The study is published in the journal Cancer Discovery.

Read entire EMBARGOED new release: Genetic Variations